| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Chalmers and Kubeck North is a Salem, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Phenomenome Discoveries, Inc. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Path-Tec is a leading provider of specimen collection kits and components. Our specialty is detailed specimen management. We understand the importance of specimen integrity so we work with laboratories to design kits that assist with proper specimen co...